Real-world assessment of sparsentan’s drug safety framework

Sparsentan has been approved for reducing proteinuria in adult patients with primary IgA nephropathy (IgAN) at risk of rapid disease progression, yet comprehensive studies evaluating its drug safety framework are lacking. Adverse event (AE) reports following the market release of sparsentan were col...

Full description

Saved in:

Bibliographic Details
Published in:	Renal failure Vol. 47; no. 1; p. 2461668
Main Authors:	Fu, Wenjing, Wang, Jingyu, Xue, Yuzhou, Pan, Dikang
Format:	Journal Article
Language:	English
Published:	England Taylor & Francis Group 01.12.2025
Subjects:	Adolescent Adult Adverse Drug Reaction Reporting Systems adverse events Angiotensin II Type 1 Receptor Blockers - adverse effects Clinical Trials, Phase III as Topic Endothelin A Receptor Antagonists - adverse effects FAERS Female Glomerulonephritis, IGA - drug therapy Humans IgA nephropathy Male pharmacovigilance Retrospective Studies sparsentan Young Adult FAERS IgA nephropathy adverse events sparsentan pharmacovigilance
ISSN:	0886-022X, 1525-6049, 1525-6049
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!